The Next Wave In Cancer Treatment - Kinase Inhibitors
This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including:
The report includes statistical information for relevant cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. The market segments provide an overview, description of kinase inhibitors currently on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the cancer industry as a whole.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2012. Historical data was provided for the years 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.
- Breast
- Colorectal
- Head/Neck
- Kidney
- Leukemia
- Liver
- Lung
- Melanoma
- Ovarian
- Pancreatic
- Prostate
- Stomach
The report includes statistical information for relevant cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. The market segments provide an overview, description of kinase inhibitors currently on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the cancer industry as a whole.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year for data was 2012. Historical data was provided for the years 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Tyrosine Kinase Inhibitors (TKIs) Market
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
What is Cancer?
Biochemistry of Cancer Cells
Carcinogen Metabolism
Causes of Cancer Growth
Environmental Factors, DNA, RNA
Cellular Oncogenes
Tumor Suppressor Genes
History and Growth of the Cancer Treatment Market
Industry Structure
Demographics and Statistics
Global Cancer Statistics
Lung Cancer
Breast Cancer
Colon/Rectal Cancer
Cancer Stats in the United States
Demographics
Aging Population
Life Expectancy and Cancer
Life Expectancy
Birth Rates
Description of Select Cancers
Breast Cancer
Colorectal Cancer
Head and Neck
Kidney
Leukemia
Liver
Lung Cancer
Melanoma
Ovarian Cancer
Pancreas
Prostate Cancer
Stomach Cancer
CHAPTER THREE: PRODUCTS
Overview
Bosulif (bosutinib)
Caprelsa (vandetanib)
Gleevec (imatinib)
Inlyta (axitinib)
Iressa (gefitinib)
Jakafi (ruxolitinib)
Nexavar (sorafenib)
Sprycel (dasatinib)
Stivarga (regorafenib)
Sutent (sunitinib)
Tarceva (erlotinib)
Tasigna (nilotinib)
Tyverb/Tykerb (lapatinib)
Votrient (pazopanib)
Xalkori (crizotinib)
Zelboraf (vemurafenib)
CHAPTER FOUR: MARKET SIZE AND GROWTH
Market Summary
Markets by Geographical Segments
U.S. Market
Europe Market
Japan Market
ROW Market
Competitive Analysis
CHAPTER FIVE: NEW DEVELOPMENTS
The Pipeline for Kinase Inhibitors
Significant Developments
Afatinib
Axitinib
Bosutinib
Cabozantinib
Crizotinib
Motesanib
Ponatinib
Regorafenib
Tivozanib
Recent NDA Activity
New Approvals
Patent Activity and Generic Development
CHAPTER SIX: ISSUES AND TRENDS
Introduction
Insurance and Reimbursement Issues
Personalized Medicine
Targeted Cancer Therapy
Pharmacogenomics
Alliances Acquisitions and Licensing Agreements
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Eli Lilly & Co.
Johnson & Johnson
Merck
Novartis
Pfizer
Patient-Reported Outcomes
Healthy Lifestyles Continue to Show Promise for Cancer Prevention
Obesity in the U.S.
U.S. Obesity Rates Differ Among Ethnic Groups
Alcohol’s Affect on Cancer Incidence
Marketing and Distribution Trends
Geographical Trends
United States
Europe
Japan
Elderly Clinical Trial Involvement
CHAPTER SEVEN:COMPANY PROFILES
Introduction
AstraZeneca plc
Bayer
Bristol-Myers Squibb Company
GlaxoSmithKline
Novartis
Pfizer, Inc.
Roche
APPENDIX:MAJOR COMPETITORS’ ADDRESSES
Introduction
Scope and Methodology
Tyrosine Kinase Inhibitors (TKIs) Market
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
What is Cancer?
Biochemistry of Cancer Cells
Carcinogen Metabolism
Causes of Cancer Growth
Environmental Factors, DNA, RNA
Cellular Oncogenes
Tumor Suppressor Genes
History and Growth of the Cancer Treatment Market
Industry Structure
Demographics and Statistics
Global Cancer Statistics
Lung Cancer
Breast Cancer
Colon/Rectal Cancer
Cancer Stats in the United States
Demographics
Aging Population
Life Expectancy and Cancer
Life Expectancy
Birth Rates
Description of Select Cancers
Breast Cancer
Colorectal Cancer
Head and Neck
Kidney
Leukemia
Liver
Lung Cancer
Melanoma
Ovarian Cancer
Pancreas
Prostate Cancer
Stomach Cancer
CHAPTER THREE: PRODUCTS
Overview
Bosulif (bosutinib)
Caprelsa (vandetanib)
Gleevec (imatinib)
Inlyta (axitinib)
Iressa (gefitinib)
Jakafi (ruxolitinib)
Nexavar (sorafenib)
Sprycel (dasatinib)
Stivarga (regorafenib)
Sutent (sunitinib)
Tarceva (erlotinib)
Tasigna (nilotinib)
Tyverb/Tykerb (lapatinib)
Votrient (pazopanib)
Xalkori (crizotinib)
Zelboraf (vemurafenib)
CHAPTER FOUR: MARKET SIZE AND GROWTH
Market Summary
Markets by Geographical Segments
U.S. Market
Europe Market
Japan Market
ROW Market
Competitive Analysis
CHAPTER FIVE: NEW DEVELOPMENTS
The Pipeline for Kinase Inhibitors
Significant Developments
Afatinib
Axitinib
Bosutinib
Cabozantinib
Crizotinib
Motesanib
Ponatinib
Regorafenib
Tivozanib
Recent NDA Activity
New Approvals
Patent Activity and Generic Development
CHAPTER SIX: ISSUES AND TRENDS
Introduction
Insurance and Reimbursement Issues
Personalized Medicine
Targeted Cancer Therapy
Pharmacogenomics
Alliances Acquisitions and Licensing Agreements
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Eli Lilly & Co.
Johnson & Johnson
Merck
Novartis
Pfizer
Patient-Reported Outcomes
Healthy Lifestyles Continue to Show Promise for Cancer Prevention
Obesity in the U.S.
U.S. Obesity Rates Differ Among Ethnic Groups
Alcohol’s Affect on Cancer Incidence
Marketing and Distribution Trends
Geographical Trends
United States
Europe
Japan
Elderly Clinical Trial Involvement
CHAPTER SEVEN:COMPANY PROFILES
Introduction
AstraZeneca plc
Bayer
Bristol-Myers Squibb Company
GlaxoSmithKline
Novartis
Pfizer, Inc.
Roche
APPENDIX:MAJOR COMPETITORS’ ADDRESSES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Sales of Kinase Inhibitor Products, 2012
Figure 1-2: World Cancer Kinase Inhibitor Market, 2007-2017
Table 1-1: World Cancer Kinase Inhibitor Market, 2007-2017
Figure 1-1: World Cancer Kinase Inhibitor Market, 2007-2017 w/ Growth Trend
CHAPTER TWO: INTRODUCTION
Table 2-1: Viruses Associated with Cancer in Humans
Figure 2-1: Approved Cancer Therapies in the United States by Primary Indication
Figure 2-2: Approved Kinase Inhibitors for Cancer Treatment in the United States by Original Indication*
Table 2-2: Total Cancer Incidence by Gender and Country, 2010 Estimates
Figure 2-3: Cancer Incidence by Gender and Country, 2010 Estimates
Table 2-3: World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both genders
Figure 2-4: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 2-4: Most Common Cancer by Region and Gender
Table 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates
Figure 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates
Table 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
Figure 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
Table 2-7: World Population by Selected Geographical Region, 2010 - 2050
Figure 2-7: World Population by Selected Geographical Region, 2010–2050
Table 2-8: Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-8: Estimated World Population by Age, 2010 and 2050
Table 2-9: Average Life Expectancy in Years by Country 1980 and 2011
Figure 2-9: Average Life Expectancy in Years by Country 1980 and 2011
Table 2-10: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2009
Table 2-11: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2009
Table 2-10: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Figure 2-12: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Table 2-11: Types of Leukemia
Table 2-12: Types of Primary Lung Cancer
Table 2-13: Malignant Conditions of the Skin
CHAPTER THREE: PRODUCTS
Table 3-1: Cancer Indicated Kinase Inhibitor Approvals by Year
Figure 3-1: Table 3-2: Leading Products by Sales, 2010 and 2012
CHAPTER FOUR: MARKET SIZE AND GROWTH
Table 4-1: World Cancer Kinase Inhibitor Market, 2007-2017
Figure 4-1: World Cancer Kinase Inhibitor Market, 2007-2017
Table 4-2: World Cancer Kinase Inhibitor Market
Figure 4-2: World Cancer Kinase Inhibitors Market
Table 4-3: U.S. Kinase Inhibitor Products by Sales, 2012
Figure 4-3: U.S. Kinase Inhibitor Products by Sales, 2012
Table 4-4: Europe Kinase Inhibitor Products by Sales, 2012
Figure 4-4: Europe Kinase Inhibitor Products by Sales, 2012
Figure 4-5: World Cancer Kinase Inhibitor Market
Figure 4-6: World Cancer Kinase Inhibitor Market
Figure 4-7: World Cancer Kinase Inhibitor Market
Table 4-5: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Shares by Market Revenues, 2012
Figure 4-8: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Shares by Market Revenues, 2012
CHAPTER FIVE: NEW DEVELOPMENTS
Table 5-1: Developments in Kinase Inhibitors, Selected Projects
Figure 5-1: Registration and Phase III Compounds in Development for Major
Indications, Distribution Estimates
Table 5-2: Recent NDA Activity: January 2011-October 2012
Table 5-3: Select New Approvals (NCE, Indications, Dosage, Formulations)
January 2010-October 2012
Table 5-4: Patent Data for Kinase Inhibitors
CHAPTER SIX: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
Table 6-1: Obesity Rates by U.S. State, 2011
CHAPTER SEVEN: COMPANY PROFILES
Figure 7-1: Cancer Kinase Inhibitor Development for Leading Companies
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Sales of Kinase Inhibitor Products, 2012
Figure 1-2: World Cancer Kinase Inhibitor Market, 2007-2017
Table 1-1: World Cancer Kinase Inhibitor Market, 2007-2017
Figure 1-1: World Cancer Kinase Inhibitor Market, 2007-2017 w/ Growth Trend
CHAPTER TWO: INTRODUCTION
Table 2-1: Viruses Associated with Cancer in Humans
Figure 2-1: Approved Cancer Therapies in the United States by Primary Indication
Figure 2-2: Approved Kinase Inhibitors for Cancer Treatment in the United States by Original Indication*
Table 2-2: Total Cancer Incidence by Gender and Country, 2010 Estimates
Figure 2-3: Cancer Incidence by Gender and Country, 2010 Estimates
Table 2-3: World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both genders
Figure 2-4: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 2-4: Most Common Cancer by Region and Gender
Table 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates
Figure 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates
Table 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
Figure 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
Table 2-7: World Population by Selected Geographical Region, 2010 - 2050
Figure 2-7: World Population by Selected Geographical Region, 2010–2050
Table 2-8: Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-8: Estimated World Population by Age, 2010 and 2050
Table 2-9: Average Life Expectancy in Years by Country 1980 and 2011
Figure 2-9: Average Life Expectancy in Years by Country 1980 and 2011
Table 2-10: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2009
Table 2-11: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2009
Table 2-10: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Figure 2-12: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Table 2-11: Types of Leukemia
Table 2-12: Types of Primary Lung Cancer
Table 2-13: Malignant Conditions of the Skin
CHAPTER THREE: PRODUCTS
Table 3-1: Cancer Indicated Kinase Inhibitor Approvals by Year
Figure 3-1: Table 3-2: Leading Products by Sales, 2010 and 2012
CHAPTER FOUR: MARKET SIZE AND GROWTH
Table 4-1: World Cancer Kinase Inhibitor Market, 2007-2017
Figure 4-1: World Cancer Kinase Inhibitor Market, 2007-2017
Table 4-2: World Cancer Kinase Inhibitor Market
Figure 4-2: World Cancer Kinase Inhibitors Market
Table 4-3: U.S. Kinase Inhibitor Products by Sales, 2012
Figure 4-3: U.S. Kinase Inhibitor Products by Sales, 2012
Table 4-4: Europe Kinase Inhibitor Products by Sales, 2012
Figure 4-4: Europe Kinase Inhibitor Products by Sales, 2012
Figure 4-5: World Cancer Kinase Inhibitor Market
Figure 4-6: World Cancer Kinase Inhibitor Market
Figure 4-7: World Cancer Kinase Inhibitor Market
Table 4-5: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Shares by Market Revenues, 2012
Figure 4-8: Top 5 Suppliers: Cancer Kinase Inhibitor Market – Shares by Market Revenues, 2012
CHAPTER FIVE: NEW DEVELOPMENTS
Table 5-1: Developments in Kinase Inhibitors, Selected Projects
Figure 5-1: Registration and Phase III Compounds in Development for Major
Indications, Distribution Estimates
Table 5-2: Recent NDA Activity: January 2011-October 2012
Table 5-3: Select New Approvals (NCE, Indications, Dosage, Formulations)
January 2010-October 2012
Table 5-4: Patent Data for Kinase Inhibitors
CHAPTER SIX: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
Table 6-1: Obesity Rates by U.S. State, 2011
CHAPTER SEVEN: COMPANY PROFILES
Figure 7-1: Cancer Kinase Inhibitor Development for Leading Companies
